Bullish indicating open at $55-$60, IPO prices at $37
Yale Podnos, the Chief Medical (TASE:BLWV) Officer of the Oncology Institute, Inc. (NASDAQ:TOI), recently purchased shares in the company. According to a filing with the Securities and Exchange Commission, Podnos acquired 9,056 shares of common stock on March 26, 2025, at a price of $1.0417 per share. The total value of this transaction amounted to approximately $9,433. The purchase comes as the company’s stock has shown remarkable momentum, with InvestingPro data showing a 258% return over the past six months.
This purchase was part of a private placement transaction, which involved the acquisition of securities directly from the company under a Securities Purchase Agreement dated March 24, 2025. As part of the agreement, Podnos also acquired warrants to purchase additional shares of common stock. The transaction was approved by the company’s board of directors and was exempt under Rule 16b-3 of the Securities Exchange Act.
Following this transaction, Podnos holds a total of 79,049 shares in the company. The acquisition reflects continued insider interest in the Oncology Institute as it navigates the healthcare sector.
In other recent news, The Oncology Institute has reported its financial results for the fourth quarter of 2024, revealing a net loss despite strategic growth initiatives. The company missed earnings per share (EPS) and revenue forecasts, with an actual EPS of -$0.14 compared to the expected -$0.08, and revenue of $100.3 million falling short of the anticipated $109.15 million. Despite these misses, the company experienced a 17% year-over-year increase in consolidated revenue for the quarter and a 21.3% increase in full-year revenue, reaching $393 million. The full-year gross profit, however, declined by 9.4% to $54 million, and the net loss was $64.6 million, although this was an improvement of $18.4 million over the previous year. Looking forward, The Oncology Institute projects 2025 revenue between $460 million and $480 million, with expectations to achieve profitability by the fourth quarter of 2025. The company has also announced strategic expansions, including new service contracts in Florida, which are expected to contribute significantly to future growth. Additionally, The Oncology Institute has taken steps to strengthen its financial position, including a $16.5 million private placement of common equity and restructuring its facility agreement to improve financial flexibility.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.